MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer.
Saved in:
| Title: | MYBL2 drives prostate cancer plasticity and identifies CDK2 as a therapeutic vulnerability in RB1-loss and neuroendocrine prostate cancer. |
|---|---|
| Authors: | German B, Singh JN, Fonseca MA, Burkhart DL, Sheahan A, Bergom H, Morel KL, Beltran H, Hwang JH, Lawrenson K, Ellis L |
| Source: | BioRxiv : the preprint server for biology [bioRxiv] 2024 Feb 02. Date of Electronic Publication: 2024 Feb 02. |
| Publication Type: | Preprint; Journal Article |
| Journal Info: | Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
